What Straumann says, and what independent research says
Straumann describes Roxolid® as an alloy of 85% titanium and 15% zirconium. 3
In its FDA 510(k) summaries, Straumann describes the Roxolid® material as a titanium–13 zirconium (Ti-13Zr) alloy. 471
The regulatory wording (Ti-13Zr) and the marketing wording (15% zirconium) differ slightly. Both describe a titanium-zirconium alloy; we show both rather than choose one.
Straumann describes Roxolid® as stronger than titanium and 'biologically superior', enabling smaller implants and less invasive treatment. 83
Independent systematic reviews of narrow titanium–zirconium implants report outcomes similar to titanium narrow implants over short follow-up (up to about 3 years). They do not show that Roxolid gives better survival.
In a double-blind randomised trial of small-diameter implants in the lower jaw, titanium–zirconium implants performed at least as well as titanium grade IV implants after 12 months (survival 98.9% vs 97.8%). 9
Follow-up was 12 months; long-term differences cannot be concluded from this study.
Why a stronger material matters in narrow implants
The rationale behind titanium–zirconium is mechanical: a thinner implant made from a stronger material. Straumann positions Roxolid for reduced-diameter and short implants, such as the Ø2.9 mm Bone Level Tapered and the 4 mm Standard Plus short implant, especially where bone augmentation might be avoided.3 Whether a narrow or short implant suits you is a clinical decision.
Would you like a dentist to assess whether this treatment suits you?
Request an assessmentRoxolid and the guarantee
Straumann's guarantee form applies Lifetime Plus terms to Roxolid® implants: replacement plus a treatment compensation if the implant fractures, with an amount that varies by market. The guarantee is in favour of the treating dentist, not the patient.10
Frequently asked questions
Is Roxolid titanium?
Is Roxolid better than titanium?
Last updated 28 Sep 2026 · How we review
Sources
- Regulatory recordFDA 510(k) K230108 — Straumann BLC and TLC Implants (510(k) summary) — U.S. Food and Drug Administration, 2023-09-14. Accessed 28 Sep 2026.
- Regulatory recordFDA 510(k) K191895 — Straumann Mini Implants — U.S. Food and Drug Administration, 2019-12-09. Accessed 28 Sep 2026.
- Manufacturer documentationStraumann® Roxolid® (material page) — Institut Straumann AG. Accessed 28 Sep 2026.
- Regulatory recordFDA 510(k) K150938 — Straumann Dental Implant System — Roxolid SLA Implants — U.S. Food and Drug Administration, 2015-07-24. Accessed 28 Sep 2026.
- Systematic reviewIegami CM et al. Survival of titanium-zirconium vs commercially pure titanium narrow-diameter implants: systematic review and meta-analysis — Clin Implant Dent Relat Res, 2017. Accessed 28 Sep 2026.
- Systematic reviewCao R et al. Clinical outcomes of titanium-zirconium narrow-diameter implants for single crowns: systematic review and meta-analysis — Br J Oral Maxillofac Surg, 2023. Accessed 28 Sep 2026.
- Regulatory recordFDA 510(k) K173961 — Straumann BLX Implant System (510(k) summary) — U.S. Food and Drug Administration, 2018-06-05. Accessed 28 Sep 2026.
- Manufacturer documentationStraumann iEXCEL™ system (product page) — Institut Straumann AG. Accessed 28 Sep 2026.
- Independent clinical studyAl-Nawas B et al. RCT of titanium-13zirconium versus titanium grade IV small-diameter bone level implants in edentulous mandibles — Clin Implant Dent Relat Res, 2012. Accessed 28 Sep 2026.
- Manufacturer documentationStraumann® Guarantee — Dental Implant System (form 152.360) — Institut Straumann AG. Accessed 28 Sep 2026.
Educational information only. The choice of implant system depends on your anatomy, restorative plan, bone quality and the clinician's assessment. This website does not recommend a specific implant for you.
